Noh Hye-Lim, Yamashita Haruyo, Goldberg Ira J
Division of Preventive Medicine and Nutrition, Columbia University College of Physicians & Surgeons, 630 West 168th Street, New York, NY 10032, USA.
Cardiovasc Drugs Ther. 2006 Dec;20(6):441-4. doi: 10.1007/s10557-006-0633-1.
Most circulating fatty acids are contained in lipoprotein triglycerides. For the heart to acquire these lipids, they must be broken down into free fatty acids via the enzyme lipoprotein lipase (LpL). Although it has long been known that hearts primarily use esterified fatty acids as fuel, different sources of fatty acids were thought to be interchangeable.
By creating mice with neonatal and acute LpL deletion we showed that lipoprotein-derived fatty acids could not be replaced by albumin-associated free fatty acids. Loss of cardiac LpL forces the heart to increase its uptake of glucose, reduce fatty acid oxidation, and eventually leads to cardiac dysfunction. In contrast, cardiomyocyte specific overexpression of an anchored form of LpL leads to excess lipid uptake, induction of fatty acid oxidation genes, and dilated cardiomyopathy.
Increasing lipid secretion from the heart or redirecting lipids to adipose tissue can alleviate this lipotoxic situation.
大多数循环中的脂肪酸包含在脂蛋白甘油三酯中。心脏要获取这些脂质,必须通过脂蛋白脂肪酶(LpL)将其分解为游离脂肪酸。尽管长期以来人们都知道心脏主要利用酯化脂肪酸作为燃料,但不同来源的脂肪酸被认为是可互换的。
通过构建新生期和急性LpL缺失的小鼠,我们发现脂蛋白衍生的脂肪酸不能被白蛋白相关的游离脂肪酸所替代。心脏LpL的缺失迫使心脏增加对葡萄糖的摄取,减少脂肪酸氧化,并最终导致心脏功能障碍。相反,心肌细胞特异性过表达一种锚定形式的LpL会导致脂质摄取过多、脂肪酸氧化基因的诱导以及扩张型心肌病。
增加心脏的脂质分泌或将脂质重新导向脂肪组织可以缓解这种脂毒性状况。